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Multiple valvular heart disease (VHD), ie, the combination of stenotic or regurgitant lesions occurring on ≥2 cardiac valves, and mixed VHD, ie, the combination of stenotic and regurgitant lesions on the same valve, 
are highly prevalent conditions. Yet, there is only limited data in the literature and 
current guidelines to support and guide clinical decision-making. This paradox is, 
at least partly, explained by the heterogeneity of these conditions in terms of com-
binations, pathogenesis, severity, surgical risk, reparability, and suitability for trans-
catheter therapies.
The aims of this article are (1) to provide a state-of-the-art review with respect 
to the pathophysiology, diagnosis (with an emphasis on pitfalls), and management 
strategies of multiple and mixed VHD and (2) to propose a standardized frame-
work for the clinician.
PATHOGENESIS AND PREVALENCE
Multiple and mixed VHD are highly prevalent conditions. In the Euro Heart Sur-
vey, multiple VHD, as defined by at least 2 moderate VHDs, was observed in 
20% of the patients with native VHD and in 17% of those undergoing interven-
tion.1 In the American Society of Thoracic Surgeons Database including 290 000 
patients who underwent surgery between 2003 and 2007, 11% had double 
valve procedures (replacement or repair), most often aortic and mitral,2 and triple 
valve surgery has been performed in 1% of cases. In a Swedish nationwide study 
based on hospital discharge codes without quantification of valvular dysfunction, 
multiple VHD accounted for 11% of patients.3 The most frequent associations 
were aortic stenosis (AS) plus aortic regurgitation (AR), AS plus mitral regurgita-
tion (MR) and AR plus MR.
Multiple valve disease is most often acquired.4 In the Euro Heart Survey,5 rheu-
matic fever was the predominant pathogenesis (51%), but degenerative VHD was 
also highly prevalent (41%). Other acquired pathogeneses, which include infective 
endocarditis, radiation therapy, drug-induced VHD, and inflammatory diseases, 
were by far less frequent. As in single VHD, a shift from rheumatic toward degen-
erative pathogenesis is currently observed in industrialized countries reflecting 
aging and the overall decreased incidence of rheumatic fever. Degenerative mitral 
annulus and leaflet calcifications often coexist with AS in the elderly patients and 
may, when severe, cause significant mitral stenosis (MS). This multiple VHD entity 
is often associated with worse prognosis and poses specific therapeutic challenges6 
because balloon commissurotomy or surgical mitral valve replacement is often not 
an option in these patients. Secondary MR and tricuspid regurgitation (TR) may 
develop in patients with aortic VHD and in patients with right ventricular volume or 
pressure overload because of left-sided or pulmonary VHD. Significant pulmonary 
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regurgitation is unusual, and acquired pathogeneses 
include endocarditis, carcinoid disease, and, rarely, left-
sided VHD-related pulmonary hypertension. Because 
of the high prevalence of coronary artery disease with 
previous myocardial infarction in patients with degen-
erative VHD, associated ischemic MR is not uncommon 
in this setting. Congenital pathogeneses are far less fre-
quent causes of multiple VHD.
Congenital (mainly bicuspid aortic valve) and degen-
erative VHDs are currently the most frequent pathogen-
eses of mixed aortic VHD among patients undergoing 
aortic valve replacement (37%–49% and 53%, respec-
tively) in industrialized countries, whereas rheumatic 
(9%–13%) and endocarditis (1%) are less frequent.4,5 
Mixed mitral VHD mainly results from rheumatic and 
degenerative processes, the latter being found almost 
exclusively in the elderly. Although the prevalence of 
adult congenital heart disease is constantly increasing 
and many of these individuals have multiple or mixed 
VHD,7 this review will focus on noncongenital multiple/
mixed VHD.
PATHOPHYSIOLOGY, DIAGNOSIS, AND 
IMAGING
The hemodynamic and clinical consequences of any 
given valvular lesion may be modulated by the con-
comitant presence of another stenotic or regurgitant 
lesion on the same valve (mixed VHD), or on another 
valve (multiple VHD). These consequences depend on 
the complex interplay of several factors, including the 
specific combination of VHD, the severity and timing of 
onset of each individual lesion, the loading conditions, 
and the ventricular systolic or diastolic performance. 
The main hemodynamic interactions that may impact 
on the diagnosis of multiple and mixed VHDs are (1) 
low-flow, low-gradient stenosis is frequent; (2) mixed 
valve disease may be associated with increased antero-
grade flow and gradient; (3) the continuity equation 
is inapplicable when transvalvular flows are unequal; 
(4) any severe valvular lesion may induce or increase 
upstream secondary MR or TR; (5) pressure half-time–
derived methods may be invalid in the presence of 
altered left ventricular (LV) compliance/relaxation or 
abnormal LV filling in the presence of mixed VHD.
Role of Imaging Modalities for 
Assessment of Multiple/Mixed VHD
Doppler Echocardiography
Doppler echocardiography is the cornerstone of the 
diagnosis of multiple and mixed VHD. As in single-
valve/single-lesion disease, echocardiography will allow 
establishing the pathogenesis, mechanisms, severity, 
progression, and repercussions of each valvular lesion. 
Echocardiography is critical in determining the indi-
cation and timing for surgery and the likelihood of 
successful valve repair or of transcatheter valve inter-
vention. However, the hemodynamic consequences of 
multiple and mixed VHD on blood flow, ventricular size, 
and function may affect the echocardiographic diagno-
sis. Several methods routinely used to assess VHD have 
not been validated in this subset of patients and may be 
misleading if not correctly interpreted in the context of 
the multiple/mixed VHD. The main diagnostic caveats in 
the echocardiographic diagnosis in multiple and mixed 
VHD are presented in Table 1.4 An integrative approach 
is even more needed than for single VHD.
Cardiac Catheterization
Cardiac catheterization is currently recommended in 
situations where noninvasive evaluation is inconclu-
sive or discordant with clinical findings8 and remains 
commonly performed in patients with multiple VHD.1 
However, cardiac output assessment by either the 
thermodilution or the Fick method, which is an essen-
tial component of the Gorlin formula for the calcula-
tion of aortic or mitral valve area, may be inaccurate 
in patients with severe TR and among those with low 
cardiac output, which are both common in multiple 
and mixed VHD. Moreover, because right heart flow 
does not equal the transvalvular flow in patients with 
mixed aortic and mixed mitral VHD, the Gorlin for-
mula is inherently inaccurate and should not be used 
in this setting.
There is growing evidence that other imaging 
modalities can be helpful in VHD when conventional 
echocardiography is inconclusive. However, there is 
currently no data on their potential role in the specific 
assessment of patients with multiple VHD. Yet, an 
accurate determination of the severity of stenotic and 
regurgitant lesions is critical, and imaging techniques 
other than standard echocardiography may prove 
helpful in difficult cases, particularly in the setting of 
low-flow situations.
Three-Dimensional Echocardiography
Three-dimensional echocardiography can be used to 
obtain more accurate assessment of aortic valve area, 
by allowing direct measurement of LV outflow tract 
area (the which is usually not circular). Using a trans-
thoracic or transesophageal approach, it may also be 
used to measure mitral valve area in rheumatic MS.9
Stress Echocardiography
Low-dose (≤20 µg/kg per min) dobutamine stress echo-
cardiography may be helpful to distinguish true severe 
from pseudosevere AS and to assess LV flow reserve, 
when the pressure gradient is low and LV ejection frac-
tion is reduced. Although there is limited (if any) specific 
data on multiple and mixed VHD, treadmill or preferably 
bicycle stress echocardiography may be indicated when 
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symptoms appear disproportionate in relation to the 
resting hemodynamics. This test may provide a mecha-
nistic explanation for the symptoms, by revealing, for 
example, a disproportionate increase in the transval-
vular pressure gradient or pulmonary arterial pressure. 
When the VHD appears severe on resting echocardiog-
raphy but the patient claims to be asymptomatic, exer-
cise testing may unmask symptoms, an abnormal blood 
pressure response to exercise, ST-segment abnormali-
ties, or exercise-induced arrhythmias.8,10–12
Table 1. Main Diagnostic Caveats in the Echocardiographic Assessment of Multiple and Mixed Valvular Diseases and Proposed Solutions Using 
Multimodality Imaging
Combination of Valve 
Lesions AS AR MS MR
AS  C: AR pressure half-time 
method unreliable
C: MS pressure half-time 
method unreliable
C: increased mitral regurgitant 
volume
S: peak aortic jet velocity 
and Doppler mean gradient 
reflect severity of both AR 
and AS
C: low-flow, low-gradient MS 
can occur
C: Increased area of MR jet 
using color-flow mapping. 
Mitral effective regurgitant 
orifice less affected than 
MR volume and color-flow 
mapping parameters
S: 3D echocardiography to 
measure mitral valve anatomic 
area and confirm MS severity
S: CMR may be used to quantify 
MR volume and fraction and 
corroborate MR severity
AR C: simplified Bernoulli 
equation for gradient 
determination might not be 
applicable if LV outflow tract 
velocity is elevated
 C: aortic regurgitant jet can be 
mistaken for MS jet
C: Doppler volumetric method 
using left-sided assessment of 
net forward flow invalid
C: Gorlin formula using 
thermodilution/Fick method 
is invalid
C: continuity equation is 
unreliable to calculate mitral 
valve area if aortic valve is 
used as the reference flow
C: mitral-to-aortic velocity time 
integral ratio unreliable
S: Continuity equation is 
applicable to assess AVA
C: MS pressure half-time 
method unreliable
S: the PISA method remains 
accurate for the assessment 
of MR
C: most echo parameters 
only reflect the severity of 
only one component of the 
disease: AS (AVA) or AR 
(regurgitant orifice area or 
volume)
S: 3D echocardiography to 
measure mitral valve anatomic 
area and confirm MS severity
S: peak aortic jet velocity 
and Doppler mean gradient 
reflect severity of both AS 
and AR
S: consider using pulmonic 
flow as the reference for the 
continuity equation
MS C: low-flow, low-gradient AS 
is common
C: MS can blunt the increase 
in pulse pressure and the LV 
dilation associated with AR
 C: mitral-to-aortic velocity time 
integral ratio unreliable
S: DSE or aortic valve calcium 
scoring by MDCT can be 
used to confirm AS severity
S: Doppler mitral gradient 
reflects severity of both MS 
and MR
MR C: mitral regurgitant jet 
should not be mistaken for 
the AS jet
C: Doppler volumetric 
method using left-sided 
assessment of net forward 
flow invalid
C: continuity equation 
unreliable
 
C: low-flow, low-gradient AS 
is common
C: pressure half-time method 
can be unreliable
C: pressure half-time method 
may not be reliable
S: DSE or aortic valve calcium 
scoring by MDCT can be 
used to confirm AS severity
S: CMR may be used 
to quantify AR and MR 
volumes and fractions and 
corroborate both AR and MR 
severity
C: Gorlin formula using 
thermodilution invalid
S: Doppler mitral gradient 
reflects severity of both MS 
and MR
This table presents the caveats in the echocardiographic assessment of a given valvular lesion (horizontal rows) in presence of concomitant valvular lesion 
(vertical columns) and the proposed solutions using multimodality imaging. 3D indicates 3-dimensional; AR, aortic regurgitation; AS, aortic stenosis; AVA, 
aortic valve area; C, caveat; CMR, cardiac magnetic resonance; DSE, dobutamine stress echocardiography; LV, left ventricular; MDCT, multidetector computed 
tomography; MR, mitral regurgitation; MS, mitral stenosis; PISA, proximal isovelocity surface area; and S, solution.
Adapted from Unger et al4 with permission. Copyright © 2011.
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Multidetector Computed Tomography
Multidetector computed tomography is increasingly 
used to assess the aortic valve calcium score when there 
is evidence of low-flow, low-gradient AS and preserved 
LV ejection fraction. High calcium scores are consistent 
with increased likelihood of severe AS (Table 2).8,13,14
Cardiac Magnetic Resonance
In patients with inadequate echocardiographic image 
quality or in case of discrepant results, cardiac mag-
netic resonance allows assessing the severity of valvu-
lar lesions, particularly of regurgitant lesions and thus 
of mixed valve disease, as well as ventricular volumes 
and systolic function.15 However, the assessment 
of regurgitant fraction and volume by calculating 
ventricular volumes may be misleading in the pres-
ence of multiple VHD because it assumes that only 
one valve is affected, and alternative methods, such 
as phase-contrast velocity mapping, should be pre-
ferred for quantifying valvular regurgitation.16 Using 
standard imaging sequences, cardiac magnetic reso-
nance allows identifying accurately serial changes in 
ventricular volumes, mass, and function reflecting the 
global burden of valvular disease and has, therefore, 
the potential to contribute to determining the opti-
mal time for surgical or transcatheter valvular inter-
vention. However, there is only limited data on the 
specific added value of cardiac magnetic resonance in 
multiple valve disease.
AS and MR
Long-standing increased afterload, which may even-
tually result in hypertrophic remodeling, dilatation, or 
dysfunction of the LV, is a hallmark of severe AS. Conse-
quently, secondary MR may develop as a result of leaflet 
tethering and mitral annular dilatation. Because of the 
high prevalence of concomitant coronary artery dis-
ease, ischemic MR is also not uncommon in the elderly 
population. Elderly patients may also present primary 
MR as a result of mitral annular calcifications or pro-
lapse (Figure 1).17 The association of severe degenera-
tive AS and MR because of chordal rupture is rare but 
generally associated with poor LV performance.18
As a direct consequence of the increased afterload 
because of AS, the transmitral systolic pressure gradient 
increases, therefore, leading, for any given mitral effec-
tive regurgitant orifice, to higher regurgitant volume. 
Moreover, the presence of significant MR may decrease 
the forward flow across the aortic valve (Figure 1). This 
MR-induced low-flow state may reduce the transaortic 
pressure gradient and yield to an underestimation of AS 
severity (Table 1). This low-flow, low-gradient AS pattern 
because of coexistent MR may occur with reduced (clas-
sical low-flow, low-gradient AS) or preserved (paradoxi-
cal low-flow, low-gradient AS) LV ejection fraction.19 In 
the presence of MR, dobutamine stress echocardiogra-
phy may fail to induce a significant increase in LV outflow 
and may thus not allow the confirmation of AS severity. 
Quantification of aortic valve calcium score by multide-
tector computed tomography may be useful to differen-
tiate true versus pseudo-severe AS in these patients with 
low-flow, low-gradient AS and concomitant significant 
MR. A typical example is shown in Figure 1.
AS and MS
This infrequent combination is usually poorly tolerated, 
and the reduction in cardiac output is usually greater 
than what is seen in isolated AS or MS. Hence, both 
aortic and mitral pressure gradients may be lower than 
expected, which can lead to underestimation of the 
severity of both AS and MS. Similar to MR, severe MS 
may lead to low LV outflow and, therefore, result in 
paradoxical low-flow, low-gradient AS. This highlights 
the need for a careful quantification of AS severity using 
an integrative approach, including aortic valve calcium 
quantification by multidetector computed tomography.
AR and MS
Whereas preload is increased by AR, it is decreased by MS. 
These opposing loading conditions may result in lower 
Table 2.  Computed Tomographic Aortic Valve Calcium Scoring Thresholds (Agatston Unit) for Anatomically Severe Aortic 
Stenosis8,13,14
 Source
Women Men
Threshold Sensitivity, % Specificity, % Threshold Sensitivity, % Specificity, %
Optimum Pawade et al13 1377 87 84 2062 80 82
ESC Guidelines 2017 1200   2000   
Clavel et al14 1274 89 81 2065 80 82
Most specific Pawade et al13 2646 51 96 3905 36 95
ESC Guidelines 2017 1600   3000   
Clavel et al14 1681 69 95 3381 59 95
Most sensitive Pawade et al13 774 95 62 1196 95 58
ESC Guidelines 2017 800   1600   
Clavel et al14 791 95 63 1661 95 70
ESC indicates European Society of Cardiology.
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LV volumes compared with isolated AR.20 In the presence 
of MS, the typical signs of AR, including increased pulse 
pressure, may be absent.21 Figure 2 shows a patient with 
rheumatic heart disease and concomitant AR and MS. In 
such cases, both the continuity equation and pressure half-
time methods are invalid to calculate mitral valve effective 
orifice area, because of the presence of concomitant sig-
nificant (≥moderate) AR (Table 1). Transthoracic 3-dimen-
sional echocardiography may be used to assess mitral valve 
anatomic orifice area and confirm MS severity (Figure 2).
Figure 1. Eighty-year-old symptomatic man with concomitant aortic stenosis, aortic regurgitation, and mitral regurgitation.  
A, Transthoracic echocardiographic parasternal long-axis view in midsystole. Left ventricular (LV) ejection fraction is 65%. The aortic valve is calcified, and there is 
a P2 mitral valve prolapse with a dilated left atrium (LA). B, Moderate mitral regurgitation with eccentric jet (orange arrow). C, Mild aortic regurgitation (orange 
arrow). D, Parasternal long-axis zoomed view of the LV outflow tract (LVOT) and aortic valve that appears severely calcified. The LVOT diameter is measured at 24.9 
mm and aortic annulus diameter at 24.4 mm. E, LVOT flow velocity by pulsed wave Doppler. The LVOT velocity time integral is 11 cm, and the calculated forward 
stroke volume in the LVOT is 54 mL. The stroke volume index is thus 30 mL/m2 (body surface area, 1.8 m2), consistent with a low-flow state. F, Continuous-wave 
Doppler of the aortic valve flow. The mean transaortic gradient is 28 mm Hg, and the aortic valve area by continuity equation is 0.75 cm2. There is thus a discor-
dant echocardiographic grading, with the concomitance of a small valve area and a low gradient. G, Parasternal short-axis view in midsystole showing a calcified 
aortic valve with restricted opening. H, Noncontrast multidetector computed tomography showing severe valve calcification (aortic valve calcium score, 2395 AU). 
On this basis, the patient was considered having true severe aortic stenosis and underwent transcatheter aortic valve replacement with a SAPIEN 3 valve. I, Mitral 
regurgitation (orange arrow) at 30 d post-valve replacement. The severity of the regurgitation was similar compared with baseline. The stroke volume increased to 
60 mL but remained in the low-flow range (33 mL/m2). The aortic valve area was 1.97 cm2, and the mean gradient decreased to 7 mm Hg. The patient who was in 
New York Heart Association class III before transcatheter valve replacement improved to class I to II 1 mo after intervention. In summary, this is a case of a patient 
with severe aortic stenosis who presented with a paradoxical (preserved LV ejection fraction) low-flow, low-gradient pattern. The low-flow state was, at least partly, 
related to the coexistence of moderate mitral regurgitation. The presence of severe aortic stenosis was confirmed by the quantification of aortic valve calcification 
by computed tomography. AO indicates aorta; RV, right ventricular.
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AR and MR
MR associated with AR may be primary or secondary to 
LV remodeling as a consequence of AR. LV relaxation and 
compliance have been shown to influence AR pressure 
half-time.22 In turn, chronic MR may lead to LV dilation 
and increase in LV compliance.23 Hence, pressure half-
time to assess AR severity should be interpreted cautiously 
in the presence of MR or in the presence of any condi-
tion altering LV relaxation/compliance. In the presence of 
severe MR, mild-to-moderate AR is usually well toler-
ated.24 However, when AR is severe, any degree of MR 
may substantially worsen the LV dilation and dysfunction. 
AR and MR both contribute to increase preload, which 
may result in accelerated LV dilatation and dysfunction. 
Furthermore, mitral valve competency normally protects 
the left atrium and the pulmonary veins from the delete-
rious effects of the increased LV pressure related to AR. 
However, the coexistence of AR and MR exacerbates the 
impact of LV volume and pressure overload on the left atri-
um, pulmonary circulation, and right chambers. Hence, 
this combination is poorly tolerated, and postoperative LV 
dysfunction is more likely to occur than in isolated valve 
regurgitation.25 In the long-term, LV function may eventu-
ally improve after double-valve surgery,26 but, in a small 
series, persisting symptoms were more frequent than in 
patients undergoing valve replacement for isolated AR, 
and survival rates were lower compared with patients with 
symptomatic MR who had been operated on.27
TR and Left-Sided VHD
The prevalence of secondary TR is high among 
patients presenting with left-sided VHD. Although it 
Figure 2. Patient with multiple mitral and aortic valve diseases.  
Fifty-six-year-old woman with concomitant rheumatic mitral and aortic valve disease. A, Transthoracic echocardiographic color Doppler apical 4-chamber view during 
diastole showing aortic regurgitation jet (yellow arrow) and accelerated transmitral flow velocities consistent with mitral stenosis (white arrow). B, Continuous wave 
Doppler signal and tracing across the mitral valve, with an 8-mm Hg mean diastolic pressure gradient, a 1.5 cm2 mitral valve area using the pressure half-time method. C, 
Continuous wave Doppler tracing across the aortic valve; mean pressure gradient was 16 mm Hg, aortic valve area was 1.5 cm2 by continuity equation method, and the 
effective regurgitant orifice was 0.20 cm2 by the proximal isovelocity surface area method (not shown). D, Three-dimensional (3D) view of the mitral valve orifice, with 
a 1.1-cm2 mitral valve area using 3D reconstruction of the mitral valve orifice (E). This case highlights the overestimation of mitral valve area using the pressure half-time 
method in the presence of concomitant aortic valve disease. Furthermore, the continuity equation method cannot be used to calculate the mitral valve area because of 
the coexistence of moderate aortic regurgitation. In such situation, 3D echocardiography and planimetry of the mitral valve anatomic orifice area can be used to cor-
roborate mitral stenosis severity. In summary, this patient had concomitant severe mitral stenosis, moderate aortic regurgitation, and mild-to-moderate aortic stenosis.
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was initially mainly studied for mitral VHD,28 there is 
now evidence that it may also occur as a result of 
aortic VHD. TR is associated with reduced long-term 
functional capacity and survival after treatment of the 
left-sided VHD.29 A complex interplay of many factors 
may contribute to the occurrence and severity of sec-
ondary TR in the setting of downstream VHD, includ-
ing pulmonary hypertension, atrial fibrillation, right 
ventricular dilatation and dysfunction, leaflet tether-
ing, annular dilatation toward the right ventricular 
free wall, or right atrial enlargement. Because TR is 
highly sensitive to changes in loading conditions, it 
has been proposed that annular dilatation and leaf-
let coaptation, rather than TR severity itself, would 
be a predictor for the future development of TR and 
would serve as a therapeutic guide.30 Thermodilution-
derived cardiac output may be erroneously low in 
patients with severe TR, which may lead to underesti-
mation of aortic valve area by the Gorlin equation and 
thus overestimation of AS severity.31
Figure 3. Patient with mixed aortic stenosis and regurgitation.  
Transthoracic echocardiographic images in a symptomatic (New York Heart Association class II and III) man with a body surface area of 1.85 m2. A, Parasternal 
long-axis color Doppler view showing a moderate aortic regurgitation. The vena contracta width is 5.8 mm. B and C, Left ventricular outflow tract diameter is 26.5 
mm, and velocity-time integral by pulsed wave Doppler is 25 cm with a calculated stroke volume of 138 mL. The aortic flow velocity time integral by continuous 
wave Doppler valve effective orifice area by continuity equation is 1.34 cm2 (indexed, 0.72 cm2/m2). Hence, the echocardiographic findings suggest the concomi-
tance of a moderate aortic regurgitation with a moderate aortic stenosis. In this case, it is challenging to establish whether or not aortic valve intervention is 
indicated. Neither the aortic regurgitation nor the aortic stenosis is severe and mandate intervention according to the guidelines. However, (D) shows a peak veloc-
ity of 4.5 m/s and a mean gradient of 44 mm Hg. These parameters provide an assessment of the severity of the overall aortic valve disease, that is, regurgitation 
plus stenosis. Indeed, the peak aortic jet velocity and mean gradient increase with both aortic stenosis and aortic regurgitation (because of increase in transvalvular 
flow). The patient was thus referred to aortic valve replacement.
D
ow
nloaded from
 http://ahajournals.org by on February 21, 2019
Circ Cardiovasc Imaging. 2018;11:e007862. DOI: 10.1161/CIRCIMAGING.118.007862 August 2018 8
Unger et al; Multiple and Mixed Valvular Heart Disease
AS and AR
Mixed aortic VHD is characterized by a combination 
of pressure and volume load that imposes a great-
er stress on the LV than that induced by isolated AS 
or AR. The stenotic component imposes a pressure 
overload that aggravates LV hypertrophy, resulting in 
decreased LV compliance and thus in a disproportion-
ate increase in LV diastolic pressure per unit of volume 
increase during diastole.32,33 Symptomatic patients 
rarely achieve a LV end-systolic dimension of 50 mm, 
which suggests that LV hypertrophy may not allow 
the LV to dilate as a result of the volume overload.33–35 
Moreover, the increase in stroke volume resulting 
from the regurgitant flow may further contribute to 
severe pressure overload even when the aortic valve 
area is >1.0 cm2. The aortic valve area reflects the 
severity of AS, whereas the effective regurgitant ori-
fice area or regurgitant volume reflects the severity of 
AR. However, none of these parameters adequately 
reflects the overall hemodynamic burden associated 
with the summation of AS and AR. However, the peak 
aortic jet velocity and mean gradient increase with 
AS but also with AR because of increase in transval-
vular flow. Hence, these parameters may be useful 
to assess the overall severity of the aortic valve dis-
ease (AS+AR)34 and have been shown to correlate 
with the outcomes.32–34 Hence, a symptomatic patient 
with moderate AS and moderate AR having a peak 
jet velocity ≥4 m/s and a mean gradient ≥40 mm Hg 
should be referred to intervention. The example of a 
patient presenting moderate AS combined with mod-
erate AR resulting in a markedly increase in transaor-
tic velocity is depicted in Figure 3.
MS and MR
MR increases the flow rate across the mitral valve. 
Because transvalvular pressure gradient is a function 
of the square of the transvalvular flow rate, left atrial 
pressure may be markedly increased in patients with 
mixed mitral VHD, resulting in severe exercise intoler-
ance through an increase in pulmonary venous and 
capillary pressure. Because of the volume overload, LV 
size is usually larger than in isolated MS. Similar to aor-
tic VHD, the association of moderate MS and moderate 
Table 3. Indications for Valve Surgery in Patients Undergoing Surgery on Another Valve When the 2 Valve Lesions Are Severe, According to the 
AHA/ACC and ESC/EACTS Guidelines8,10,11
Valve Lesion 2014–2017 AHA/ACC Guidelines 2017 ESC/EACTS Guidelines
AS AVR is indicated for patients with severe AS when undergoing 
other cardiac surgery (class I, LOE B)
Surgical AVR is indicated in patients with severe AS undergoing 
surgery of the ascending aorta or on another valve (class I, LOE C)
AR AVR is indicated for patients with severe AR (stage C or D) 
while undergoing cardiac surgery for other indications (class I, 
LOE C)
Surgical aortic valve replacement or repair is indicated in patients 
with severe AR undergoing surgery of the ascending aorta or on 
another valve (class I, LOE C)
MS Concomitant mitral valve surgery is indicated for patients with 
severe MS undergoing other cardiac surgery (class I, LOE C)
Severe concomitant aortic VHD or severe combined tricuspid 
stenosis and regurgitation requiring surgery is a contraindication 
to PMC
In patients with severe MS combined with severe aortic VHD, mitral 
valve surgery is preferable when it is not contraindicated
In patients with severe TR, PMC may be considered in selected 
patients with sinus rhythm, moderate left atrial enlargement, and 
functional TR secondary to pulmonary hypertension. In other cases, 
surgery of both valves is preferred
MR Concomitant mitral valve repair or replacement is indicated in 
patients with chronic severe primary MR undergoing cardiac 
surgery for other indications (class I, LOE B)
Severe primary MR: not specifically mentioned
Mitral valve surgery is reasonable for patients with chronic 
severe secondary MR (stages C and D) who are undergoing 
AVR (class IIa, LOE C)
Mitral valve surgery is indicated in patients with severe secondary 
MR undergoing CABG and LVEF >30% (class I, LOE C). No 
recommendation is made in case of concomitant other valvular 
surgery
TR Tricuspid valve surgery is recommended for patients with severe 
TR (stages C and D) undergoing left-sided valve surgery (class 
I, LOE C)
Tricuspid valve surgery is indicated in patients with severe primary 
or secondary TR undergoing left-sided valve surgery (class I, LOE C)
TS Tricuspid valve surgery is recommended for patients with severe 
TS at the time of operation for left-sided VHD (class I, LOE C)
Intervention on the tricuspid valve is usually performed at the 
time of intervention on the other valves in patients who are 
symptomatic, despite medical therapy
Balloon commissurotomy can be considered in the rare cases with 
anatomically suitable valves when additional MS can also be treated 
interventionally
ACC indicates American College of Cardiology; AHA, American Heart Association; AR, aortic regurgitation; AS, aortic stenosis; AVR, aortic valve replacement; 
CABG, coronary artery bypass grafting; EACTS, European Association for Cardio-Thoracic Surgery; ESC, European Society of Cardiology; LOE, level of evidence; 
LVEF, left ventricular ejection fraction; MR, mitral regurgitation; MS, mitral stenosis; PMC, percutaneous mitral commissurotomy; TR, tricuspid regurgitation; TS, 
tricuspid stenosis; and VHD, valvular heart disease.
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MR may be hemodynamically and clinically significant, 
and some patients with seemingly nonsevere mixed 
mitral valve disease may complain of exertional dyspnea 
or fatigue, which has been, at least partly, attributed 
to flow-dependent increases in the transmitral pressure 
gradient.36 Because LV and left atrial compliances may 
be altered in the presence of significant MR37 and pres-
sure half-time is highly influenced by LV or left atrial 
compliance, mitral valve area derived from pressure 
half-time may not be reliable to assess the severity of 
concomitant MS.38
The mitral valve effective orifice area measured by the 
continuity equation (stroke volume measured in the LV 
outflow tract) may overestimate the severity of MS in 
the presence of concomitant MR (Table 1). The mitral 
valve anatomic orifice area measured by 3-dimensional 
transthoracic or transesophageal echocardiography may 
be used to corroborate MS severity in this context. As 
in patients with mixed aortic VHD, the peak transmitral 
velocity, mean gradient, or mitral velocity-time integral 
may provide an assessment of the overall severity of the 
mixed mitral VHD.
MANAGEMENT STRATEGY
General Principles
The limited evidence on medical, surgical, and inter-
ventional management is emphasized by the C level of 
evidence given in most recommendations made by the 
American Heart Association/American College of Cardiol-
ogy and European Society of Cardiology/European Asso-
ciation for Cardio-Thoracic Surgery guidelines (Tables  3 
and 4).8,10,11 Because of the large number of possible 
combinations of valve lesions, a standardized approach 
cannot be proposed. Nevertheless, the clinician may face 
one of the following 3 clinical scenarios (Figure 4)39:
1. Two or more severe lesions are present. In this sit-
uation, the likelihood of severe functional intoler-
ance is high if one of the lesions is left untreated. 
Therefore, addressing the 2 (or more) lesions dur-
ing the intervention has been given a class I rec-
ommendation in current European and American 
guidelines (Table 3).
2. One severe lesion is associated with ≥1 non-
severe lesion(s). In this common scenario, the 
Figure 4.  Clinical scenarios and proposed decision-making process in the management of patients with multiple valvular heart disease.  
BNP indicates brain natriuretic peptide; CMR, cardiac magnetic resonance; LV, left ventricular; MDCT, multidetector computed tomography; and RV, right ventricular.
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management of the most severely diseased 
valve is defined by current guidelines. The man-
agement of the less-than-severe lesion(s) is less 
straightforward, and, in most situations, a class 
II recommendation has been given for interven-
tion (Table 4).
3. If ≥2 moderate lesions are present and if the overall 
hemodynamic burden imposed by these lesions is 
believed to be the main cause of the symptoms or 
LV systolic dysfunction, a surgical or transcatheter 
valve intervention could be considered. The latter 
scenario, whose exact prevalence is unknown, is 
not covered by current guidelines. In this setting, 
it is of particular importance to determine the 
global consequences of the lesions. This includes 
careful assessment of ventricular volumes and 
pulmonary pressure, natriuretic peptides mea-
surements, and, in selected cases, the assessment 
of functional capacity, maximal oxygen consump-
tion, and pulmonary pressure during exercise, 
although there is only limited literature in the 
specific setting of multiple valve disease.
Similarly, mixed VHD may present as (1) the com-
bination of severe stenosis and regurgitation, (2) the 
combination of severe stenosis (or regurgitation) and 
nonsevere regurgitation (or stenosis), and (3) the com-
bination of moderate stenosis and moderate regur-
gitation. The first 2 scenarios should be managed 
following the current guideline recommendations 
applicable to the most severe lesion. Although the 
combination of aortic or mitral moderate stenosis and 
regurgitation is not a classical indication for interven-
tion, this scenario may be associated with symptoms, 
reduced exercise tolerance, LV repercussions, and pul-
monary hypertension and, thereby, intervention may 
be considered (Figure 4).
Heart Team Approach and How to Follow 
the Patients
A collaborative approach between cardiologists and 
cardiac surgeons is critical in the management of 
patients with multiple and mixed VHD. The situa-
tion is further complicated by the high prevalence of 
coronary artery disease. The Heart Team-based man-
agement strategy is now recommended by current 
guidelines.8,10,11 The decision-making in patients with 
multiple and mixed VHD should be individually tai-
Table 4. Indications for Concomitant Valve Surgery on Less-Than-Severe Valve Lesions in Patients Undergoing Surgery on Another Valve, 
According to the AHA/ACC and ESC/EACTS Guidelines8,10,11
Valve Lesion 2014–2017 AHA/ACC Guidelines 2017 ESC/EACTS Guidelines
AS AVR is reasonable for patients with moderate AS who are 
undergoing other cardiac surgery (class IIa, LOE C)
Surgical AVR should be considered in patients with moderate AS 
undergoing surgery of the ascending aorta or another valve, after 
Heart Team decision (class IIa, LOE C)
In cases with severe MS with moderate aortic VHD, PMC can be 
performed to postpone the surgical treatment of both valves
AR AVR is reasonable in patients with moderate AR who are 
undergoing other cardiac surgery (class IIa, LOE C)
Not mentioned
MS Concomitant mitral valve surgery may be considered for patients 
with moderate MS (MV area, 1.6–2.0 cm2) undergoing other 
cardiac surgery (class IIb, LOE C)
Not mentioned
MR Concomitant mitral valve repair is reasonable in patients with 
chronic moderate primary MR (stage B) undergoing cardiac 
surgery for other indications (class IIa, LOE C)
Primary MR: not mentioned
Mitral valve repair may be considered for patients with chronic 
moderate secondary MR (stage B) who are undergoing other 
cardiac surgery (class IIb, LOE C)
The potential impact of mitral valve intervention (surgery and 
catheter intervention) on survival in patients with secondary MR 
needs to be evaluated
TR Tricuspid valve repair can be beneficial for patients with mild, 
moderate, or greater functional TR (stage B) at the time of left-
sided valve surgery with either (1) tricuspid annular dilation or (2) 
prior evidence of right heart failure (class IIa, LOE B)
Tricuspid valve surgery should be considered in patients with 
moderate primary TR undergoing left-sided valve surgery (class IIa, 
LOE C)
Tricuspid valve repair may be considered for patients with moderate 
functional TR (stage B) and pulmonary artery hypertension at the 
time of left-sided valve surgery (class IIb, LOE C)
Tricuspid valve surgery should be considered in patients with mild 
or moderate secondary TR with dilated annulus (≥40 mm or >21 
mm/m2) undergoing left-sided valve surgery (class IIa, LOE C)
Tricuspid valve surgery may be considered in patients undergoing 
left-sided valve surgery with mild or moderate secondary TR, even 
in the absence of annular dilatation when previous recent right 
heart failure has been documented (class IIb, LOE C)
TS Not mentioned Not mentioned
ACC indicates American College of Cardiology; AHA, American Heart Association; AR, aortic regurgitation; AS, aortic stenosis; AVR, aortic valve replacement; 
EACTS, European Association for Cardio-Thoracic Surgery; ESC, European Society of Cardiology; LOE, level of evidence; MR, mitral regurgitation; MS, mitral 
stenosis; PMC, percutaneous mitral commissurotomy; TR, tricuspid regurgitation; TS, tricuspid stenosis; and VHD, valvular heart disease.
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lored, including imaging and clinical factors discussed 
here above.
Because of the paucity of data on its natural his-
tory, the appropriate timing for the follow-up visits 
of patients with multiple and mixed VHD is unclear. 
When one lesion is clearly predominant, the follow-
up should be made in accordance to current guide-
lines. However, when severity of lesions is balanced, 
the combination may have detrimental consequences, 
and interval between follow-up visits should be short-
er than in single-valve/single-lesion disease. Similarly, 
high event rates may be expected in patients with the 
combination of moderate AS and moderate AR, and 
more frequent serial evaluations are thus warranted. 
The follow-up of patients with multiple VHD should 
be performed in dedicated and structured outpatient 
heart valve clinics,40 linked to comprehensive multi-
disciplinary inpatient teams, in the setting of Heart 
Valve Centers.41
Whether or not leaving unoperated a less-than-severe 
valve lesion requires the integration of numerous factors, 
including the natural history of the unoperated valve and 
the possible changes in MR or TR severity after treatment 
of a downstream valvular lesion, the life expectancy and 
comorbidities, the individual surgical risk profile, the pos-
sibility of repair, the increased risk of redo surgery, and 
the feasibility of transcatheter approaches (Figures 4 and 
5). All these factors should be integrated by the multidis-
ciplinary heart valve team. Future studies are needed to 
determine whether simultaneous or staged transcatheter 
aortic, mitral, or tricuspid valve interventions will improve 
outcomes in patients with multiple VHD.
CONCLUSIONS
Multiple and mixed VHDs are highly prevalent. Where-
as rheumatic heart disease remains the most prevalent 
pathogenesis in developing countries, degenerative 
pathogeneses are more prevalent in industrialized 
regions. Hemodynamic interactions may alter the clini-
cal expression of each singular lesion, and the clinician 
should be aware of these interactions that may impact 
the diagnosis. Patients with multiple or mixed VHD 
should be followed in heart valve clinics. A case-by-case 
therapeutic management strategy should be made by a 
Heart Valve team, taking into account multiple factors, 
including the severity of each single valvular lesion, the 
individual risk profile, the increased long-term morbid-
ity of multiple prostheses, and the natural history of 
each valvular lesion if left untreated (Figure 4). Current 
and future advances in transcatheter valve therapies are 
likely to change the therapeutic approach of multiple 
VHD, but there is currently no evidence-based manage-
ment strategy in this setting.
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